Glenmark Pharma US unit launches Lacosamide oral solution used to treat seizures – CNBC TV18
| Company | Value | Change | %Change |
|---|
The company said the solution is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/ml of UCB, Inc. It is used to treat partial onset seizures as well as primary generalised tonic-clonic seizures.
As per the IQVIA’s yearly-sales data till October 2024, the Vimpat Oral Solution 10mg/ml market witnessed annual sales of around $57 million.
Marc Kikuchi, the company’s president and business head in North America, said, the pharma firm is excited to announce the launch of the oral solution, strengthening its commitment to bring quality and affordable alternatives for patients to the market.
On another note, last week, Glenmark Pharma said the first clinical data from the Phase 1 study of Trispecific TREAT Antibody, ISB 2001, showed a high overall response rate (ORR) with durable responses and favourable safety profile in patients with heavily pretreated Multiple Myeloma.
The initial results from 20 patients treated as of October 1, 2024, demonstrated an overall response rate of 75% across all doses tested. The doses ranged from 0.005 to 1.2 mg per kg. This came with a stringent complete remission (sCR) and complete remission (CR)rate of 20%.
Data suggests that the ISB 2001 could compare favourably with approved bispecific options, Glenmark said.
Glenmark Pharma shares were trading 1.23% higher at ₹1,536.80 apiece on Monday, December 16. The stock has gained 79.61% this year, so far.
Also Read: Why Citi sees 12% downside in the stock of India’s largest IT services firm
